[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:myc-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"MYC Gene",19,18,[8,16,23,30,36,42,48,55,61,67,73,79,85,91,97,103,109,115,121],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06249191","Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:09.641312Z","2026-07-19T19:36:05.128454Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05687136","Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors",[20],"Phase 1","2026-08-26T02:17:30.145302Z","2026-07-05T05:32:16.811559Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06687772","CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant",[27],"Phase 2","2026-08-26T02:15:40.343619Z","2026-05-05T02:43:27.846837Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07147231","Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer",[12],"2026-08-26T02:18:46.948970Z","2026-05-05T02:43:27.838424Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[27],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.813302Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06045247","Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit\u002FFrail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma",[27],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:27.172301Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT05382338","A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss",[52],"Phase 3","2026-08-26T02:16:59.895916Z","2026-05-05T02:43:27.063287Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05800366","A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma",[27],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:26.740303Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06649812","Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and\u002For Refractory Aggressive B-cell Lymphoma",[27],"2026-08-26T02:16:17.877565Z","2026-06-16T05:54:07.922088Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05600686","Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma",[27],"2026-08-26T02:16:21.385056Z","2026-05-05T02:43:29.693214Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05890352","Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment",[27],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:28.725480Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT05755087","Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma",[20],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:27.642521Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07069699","Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene",[12],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:27.175695Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[27],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06788964","Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)",[27],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.700465Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT03223610","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed\u002FRefractory B-cell Lymphoma",[12],"2026-08-26T02:17:15.156099Z","2026-05-05T02:43:29.367349Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06161519","PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications",[12],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:28.398018Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[27],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.687370Z",{"nct_id":122,"title":123,"phases":124,"status":125,"updated_at":126,"content_modified":127},"NCT04739813","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed\u002FRefractory B-cell Lymphoma",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:23:28.660374Z","2026-05-05T02:43:28.883413Z"]